Cargando…
Policy issues in the development and adoption of biomarkers for molecularly targeted cancer therapies : workshop summary /
A long-held goal in oncology has been to develop therapies that target the specific abnormalities in each patient's cancer rather than simply treating cancers based on the tissue of origin. In the past decade, advances in technology have enabled researchers to relatively quickly and inexpensive...
| Clasificación: | Libro Electrónico |
|---|---|
| Autores principales: | , , |
| Autor Corporativo: | |
| Formato: | Electrónico Congresos, conferencias eBook |
| Idioma: | Inglés |
| Publicado: |
Washington, D.C. :
National Academies Press,
[2015]
|
| Temas: | |
| Acceso en línea: | Texto completo |
MARC
| LEADER | 00000cam a2200000 i 4500 | ||
|---|---|---|---|
| 001 | EBOOKCENTRAL_ocn923137752 | ||
| 003 | OCoLC | ||
| 005 | 20240329122006.0 | ||
| 006 | m o d | ||
| 007 | cr un||||||||| | ||
| 008 | 150702s2015 dcua obt 100 0 eng | ||
| 040 | |a NLM |b eng |e rda |e pn |c NLM |d EBLCP |d OCLCO |d SFB |d OCLCO |d OCLCF |d OCLCO |d VT2 |d OCLCQ |d OCLCO |d MERUC |d ZCU |d OCLCA |d U3W |d OCLCA |d STF |d WRM |d COCUF |d EZ9 |d ICG |d IDB |d OCLCQ |d NLM |d OCLCO |d OCLCA |d LVT |d OCLCA |d TKN |d DKC |d OCLCQ |d HS0 |d OCLCQ |d OCLCO |d UKAHL |d OCLCQ |d OCLCO |d OCLCQ |d OCLCO |d OCLCL | ||
| 016 | 7 | |a 101662905 |2 DNLM | |
| 020 | |a 9780309368582 | ||
| 020 | |a 0309368588 | ||
| 020 | |z 9780309368575 | ||
| 020 | |z 030936857X | ||
| 029 | 0 | |a NLM |b 101662905 | |
| 029 | 1 | |a DEBBG |b BV044185255 | |
| 029 | 1 | |a AU@ |b 000066759465 | |
| 029 | 1 | |a AU@ |b 000068807857 | |
| 035 | |a (OCoLC)923137752 | ||
| 042 | |a pcc | ||
| 043 | |a n-us--- | ||
| 050 | 4 | |a RC270.8 ǂb P65 2014eb | |
| 060 | 0 | 0 | |a 2015 J-964 |
| 060 | 1 | 0 | |a QZ 267 |
| 082 | 0 | 4 | |a 616.994075 |
| 049 | |a UAMI | ||
| 100 | 1 | |a Nass, Sharyl J., |e author. | |
| 245 | 1 | 0 | |a Policy issues in the development and adoption of biomarkers for molecularly targeted cancer therapies : |b workshop summary / |c Sharyl J. Nass, Jonathan Phillips, and Margie Patlak, rapporteurs ; National Cancer Policy Forum, Board of Health Care Services, Institute of Medicine of the National Academies. |
| 264 | 1 | |a Washington, D.C. : |b National Academies Press, |c [2015] | |
| 300 | |a 1 online resource (1 PDF file (xx, 85 pages)) : |b illustrations | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 500 | |a Title from PDF title page. | ||
| 504 | |a Includes bibliographical references. | ||
| 520 | 3 | |a A long-held goal in oncology has been to develop therapies that target the specific abnormalities in each patient's cancer rather than simply treating cancers based on the tissue of origin. In the past decade, advances in technology have enabled researchers to relatively quickly and inexpensively determine, in minute detail, the genetic makeup of tumors. Although relatively few targeted cancer therapies are currently available in the clinic and it is not yet clear whether all cancers are driven by genetic changes that can be targeted, there is widespread optimism in the cancer community that this new ability to assess the genetic abnormalities in tumors will ultimately lead to better cancer treatments and improved patient outcomes. Policy Issues in the Development and Adoption of Biomarkers for Molecularly Targeted Cancer Therapies is the summary of a workshop convened in November 2014 by the Institute of Medicine's National Cancer Policy Forum to discuss recent trends in the development and implementation of molecularly targeted cancer therapies and explore potential policy actions to address specific challenges. This report highlights the presentations and discussions at the workshop. | |
| 536 | |a This project was supported by Contract No. HHSN261200900003C and Contract No. HHSN263201200074I (Task Order No. HHSN26300052) between the National Academy of Sciences and the Centers for Disease Control and Prevention and the National Cancer Institute/National Institutes of Health, respectively, and by the American Association for Cancer Research, the American Cancer Society, the American Society for Radiation Oncology, the American Society of Clinical Oncology, the American Society of Hematology, the Association of American Cancer Institutes, AstraZeneca, Bristol-Myers Squibb, the Cancer Support Community, C-Change, the CEO Roundtable on Cancer, EMD Serono, Helsinn Healthcare SA, the LIVESTRONG Foundation, the National Comprehensive Cancer Network, Novartis Oncology, the Oncology Nursing Society, and Sanofi Oncology. The views presented in this publication do not necessarily reflect the views of the organizations or agencies that provided support for the activity. | ||
| 588 | 0 | |a Version viewed September 25, 2015. | |
| 505 | 0 | |a Front Matter; Reviewers; Acknowledgments; Contents; Boxes, Figures, and Tables; Acronyms; Workshop Summary; INTRODUCTION; MOLECULAR BIOLOGY REVOLUTION IN CANCER DIAGNOSIS AND TREATMENT; Lessons Learned from Single Analyte Tests; Next-Generation Sequencing; RNA Sequencing Tests; Tests for Circulating Tumor DNA; Business Climate for Developing Diagnostic Tests; CHALLENGES IN BIOMARKER TEST DEVELOPMENT; Setting Standards; Assessing Analytical Validity, Clinical Validity, and Clinical Utility; Sharing Data; REGULATORY OVERSIGHT CHALLENGES; Evolving Regulation of Laboratory-Developed Tests | |
| 505 | 8 | |a Companion DiagnosticsCLINICAL IMPLEMENTATION CHALLENGES; Insufficient or Inadequate Specimens; Tsunami of Information; Choosing the Best Test; Time Delays; Lack of Resources; Reporting Test Results; Incidental Findings; REIMBURSEMENT CHALLENGES; Lack of Evidence; Investigational and Off-Label Uses; Incidental Findings; Greater Expense, But Not Necessarily Greater Value; GATHERING THE EVIDENCE: INNOVATIVE CLINICAL TRIALS; Basket Trials; Lung-MAP Umbrella Trial; Challenges with Basket and Umbrella Trials; GATHERING THE EVIDENCE: COVERAGE DECISIONS; Coverage with Evidence Development | |
| 505 | 8 | |a The MolDx Approach to Test ReimbursementGreen Park Collaborative Recommendations; GATHERING THE EVIDENCE: DATABASES AND REGISTRIES; My Cancer Genome; ClinGen; Targeted Agent and Molecular Profiling Utilization Registry; Challenges in Using Databases; EDUCATION AND CLINICAL DECISION SUPPORT NEEDS; Guidelines; Treatment Pathways; RESEARCH NEEDS; CLOSING REMARKS; REFERENCES; Appendix: Workshop Statement of Task and Agenda; POLICY ISSUES IN THE DEVELOPMENT AND ADOPTION OF MOLECULARLY TARGETED THERAPIES FOR CANCER | |
| 590 | |a ProQuest Ebook Central |b Ebook Central Academic Complete | ||
| 650 | 0 | |a Cancer |x Treatment |z United States |v Congresses. | |
| 650 | 0 | |a Cancer |x Genetic aspects |v Congresses. | |
| 650 | 0 | |a Biochemical markers |v Congresses. | |
| 650 | 1 | 2 | |a Neoplasms |x drug therapy |
| 650 | 2 | 2 | |a Molecular Targeted Therapy |
| 650 | 6 | |a Cancer |x Traitement |z États-Unis |v Congrès. | |
| 650 | 6 | |a Cancer |x Aspect génétique |v Congrès. | |
| 650 | 6 | |a Marqueurs biologiques |v Congrès. | |
| 650 | 7 | |a Biochemical markers |2 fast | |
| 650 | 7 | |a Cancer |x Genetic aspects |2 fast | |
| 650 | 7 | |a Cancer |x Treatment |2 fast | |
| 651 | 7 | |a United States |2 fast |1 https://id.oclc.org/worldcat/entity/E39PBJtxgQXMWqmjMjjwXRHgrq | |
| 655 | 2 | |a Congress | |
| 655 | 7 | |a proceedings (reports) |2 aat | |
| 655 | 7 | |a Conference papers and proceedings |2 fast | |
| 655 | 7 | |a Conference papers and proceedings. |2 lcgft | |
| 655 | 7 | |a Actes de congrès. |2 rvmgf | |
| 700 | 1 | |a Phillips, Jonathan |c (Public health researcher), |e author. |1 https://id.oclc.org/worldcat/entity/E39PCjHv4X9p9QDft8j9vh6KYd | |
| 700 | 1 | |a Patlak, Margie, |e author. | |
| 710 | 2 | |a National Cancer Policy Forum (U.S.), |e organizer. | |
| 711 | 2 | |a Policy Issues in the Development and Adoption of Molecularly Targeted Therapies for Cancer (Workshop) |d (2014 : |c Washington, D.C.) | |
| 758 | |i has work: |a Policy issues in the development and adoption of biomarkers for molecularly targeted cancer therapies (Text) |1 https://id.oclc.org/worldcat/entity/E39PCH64YbK84VghWjy4WhqHbq |4 https://id.oclc.org/worldcat/ontology/hasWork | ||
| 856 | 4 | 0 | |u https://ebookcentral.uam.elogim.com/lib/uam-ebooks/detail.action?docID=3439842 |z Texto completo |
| 938 | |a Askews and Holts Library Services |b ASKH |n AH36564381 | ||
| 938 | |a EBL - Ebook Library |b EBLB |n EBL3439842 | ||
| 994 | |a 92 |b IZTAP | ||